Paclitaxel poliglumex

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Paclitaxel poliglumex
Accession Number
DB13809
Description
Not Available
Type
Small Molecule
Groups
Experimental, Investigational
Synonyms
Not Available
External IDs
  • CT-2103

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.
AmsacrineThe risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel poliglumex.
AnastrozoleThe risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel poliglumex.
Arsenic trioxideThe risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex.
BevacizumabThe risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.
BleomycinThe risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel poliglumex.
BortezomibThe risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel poliglumex.
BusulfanThe risk or severity of cardiotoxicity can be increased when Busulfan is combined with Paclitaxel poliglumex.
CabazitaxelThe risk or severity of cardiotoxicity can be increased when Cabazitaxel is combined with Paclitaxel poliglumex.
CapecitabineThe risk or severity of cardiotoxicity can be increased when Capecitabine is combined with Paclitaxel poliglumex.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
L01CD03 — Paclitaxel poliglumex
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
TQ64FZ98ZN
CAS number
263351-82-2
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Fallopian Tube Undifferentiated Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Ovarian Undifferentiated Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIIA Fallopian Tube Cancer / Stage IIIA Fallopian Tube Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIA Primary Peritoneal Cancer / Stage IIIA Primary Peritoneal Cancer AJCC v7 / Stage IIIB Fallopian Tube Cancer / Stage IIIB Fallopian Tube Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIB Primary Peritoneal Cancer / Stage IIIB Primary Peritoneal Cancer AJCC v7 / Stage IIIC Fallopian Tube Cancer / Stage IIIC Fallopian Tube Cancer AJCC v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IIIC Primary Peritoneal Cancer / Stage IIIC Primary Peritoneal Cancer AJCC v7 / Stage IV Fallopian Tube Cancer / Stage IV Fallopian Tube Cancer AJCC v6 and v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Primary Peritoneal Cancer / Stage IV Primary Peritoneal Cancer AJCC v7 / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3Unknown StatusTreatmentLung Cancers4
3Unknown StatusTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer1
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentBreast Cancer / Metastatic Breast Cancer1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2CompletedTreatmentNeoplasms, Ovarian1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on June 23, 2017 14:49 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates